Adam Gault Bernstein upgraded Edwards Lifesciences ( NYSE: EW ) to market perform from underperform, commenting that it now saw the risk-reward for the stock as more balanced. The investment firm said its prior underperform rating had been based on a view that the transcatheter.
Back to Health Page
